Maxcyte (MXCT) Non-Current Debt (2020)

Maxcyte's (MXCT) quarterly Non-Current Debt came in at $4.9 million in Q4 2020.

Maxcyte (MXCT) Non-Current Debt (2020) Analysis & Trends

Maxcyte (MXCT) has 1 years of Non-Current Debt data on file, last reported at $4.9 million in Q4 2020.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $4.9 million in Q4 2020; TTM through Dec 2020 was $4.9 million, a N/A change from a year earlier, with the FY2020 full-year figure at $4.9 million, changed N/A from the prior year.
Non-Current Debt for Q4 2020 stood at $4.9 million.
Over the last five years, Non-Current Debt for MXCT reached as high as $4.9 million in Q4 2020 and fell as low as $4.9 million in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	29.64 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	14.22 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	26.17 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	10.99 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	598.50 Mn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	10.13 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	3.18 Bn
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	8.07 Bn
10	Maxcyte	110.62 Mn	110.62 Mn	8.08 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	4.92 Mn